Using catecholamine based hypotheses to pharmacologically address the cognitive impairments of patients with schizophrenia published by us 1998 we have tested a number of glutamatergic, noradrenergic, serotonergic and cholinergic compounds. Our efforts have resulted in several research reports informing the field on the effectiveness, or lack thereof, of various augmentation approaches.

We continue to investigate new strategies to improve the cognitive functions of patients with schizophrenia. Ongoing clinical trials are open to patients at Mount Sinai Hospital and the surrounding New York area. In addition, we are continuing with our augmentation study for severely ill patients with schizophrenia who fail to respond to clozapine treatment and expect completion of this study in the fall of 2008.